Vistagen Therapeutics Inc   (VTGN)
Other Ticker:  
Price: $5.0700 $-0.04 -0.783%
Day's High: $5.31 Week Perf: 0.5 %
Day's Low: $ 5.02 30 Day Perf: 6.07 %
Volume (M): 259 52 Wk High: $ 24.71
Volume (M$): $ 1,311 52 Wk Avg: $3.09
Open: $5.12 52 Wk Low: $0.10

 Market Capitalization (Millions $) 149
 Shares Outstanding (Millions) 29
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) 58
 Capital Exp. (TTM) (Millions $) 1

Vistagen Therapeutics Inc
Vistagen Therapeutics Inc is a biopharmaceutical company that specializes in the development of innovative therapies for mental health disorders. The company focuses on addressing the significant unmet medical needs in the field of psychiatry by utilizing a unique approach called pharmacological stress system modulation. Vistagen's aim is to develop safe and effective treatments for a variety of mental health conditions, including depression, anxiety, and substance use disorders. The company is dedicated to advancing the understanding of these disorders and improving the lives of patients through their cutting-edge therapeutic solutions.

   Company Address: 343 Allerton Avenue South San Francisco 94080 CA
   Company Phone Number: 577-3600   Stock Exchange / Ticker: NASDAQ VTGN


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Vistagen Therapeutics Inc

Revolutionizing the Treatment Landscape: How Vistagen Therapeutics Inc is Transforming Mental Health Care

In an exciting turn of events, Vistagen Therapeutics Inc has revealed impressive revenue figures of $0.4114 million in their third quarter of the 2024 earnings season. This marks a significant improvement for the company compared to the same period last year when they reported a deficit of $-9.761 million. This positive revenue growth is a testament to Vistagen's dedication and innovation in the field of neuroscience.
Vistagen Therapeutics Inc, a late clinical-stage biopharmaceutical company, is making waves in the market by pioneering groundbreaking therapies for psychiatric and neurological disorders. Their commitment to developing first-in-class treatments reflects their mission to bring hope and relief to individuals suffering from mental health conditions.

Vistagen Therapeutics Inc

Vistagen Therapeutics Inc Achieves Remarkable Financial Milestone with Revenue of $0.2777 Million in Q3 2023

Vistagen Therapeutics Inc, a late clinical-stage biopharmaceutical company based in South San Francisco, has recently reported its financial results for the most recent fiscal period. The company recorded a revenue of $0.2777 million during this period, compared to a deficit of $-17.483 million reported in the corresponding period last year. The net deficit for the recent period was $-6.588 million.
The positive change in financial performance indicates progress and improvement for Vistagen Therapeutics Inc. This could be attributed to various factors, such as successful clinical trials or the launch of new products in the market. The company's ability to reduce its overall deficit is a promising sign for its future financial outlook.

Vistagen Therapeutics Inc

Vistagen Therapeutics Inc Successfully Narrows Deficit and Boosts Financial Performance Amidst Challenging Times

Vistagen Therapeutics Inc (VTGN) has recently released its financial results for the fiscal period closing June 30th, 2023, and the numbers are undoubtedly impressive. The company has managed to significantly reduce its loss per share compared to the previous year, showing a decrease from $-2.87 to $-0.94 per share. Additionally, the earnings per share have improved from $-1.71 in the prior quarter to the current value.
Despite the challenging economic conditions caused by the pandemic, VTGN has been able to maintain its revenue levels, with no significant changes reported compared to the same quarter a year ago. This stability is a remarkable achievement in itself, as many businesses have struggled to keep their revenues intact during these uncertain times. Furthermore, the sequential improvement from a loss of $-0.31 million to $0.00 million indicates a positive trend for the company's financials.
One of the most notable aspects of Vistagen Therapeutics Inc's performance is the significant reduction in its net deficit. During the fiscal period closing June 30th, 2023, the company reported a net deficit of $-6.903 million, which is significantly lower than the $-19.776 million deficit reported in the same quarter a year ago. This demonstrates that VTGN has made significant progress in managing its expenses and improving its bottom line.


Vistagen Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com